ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
Articles by proactiveinvestors
OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
ReNeuron Treats Third Stroke Patient In Phase I Trials Of Stem Cell Therapy
ReNeuron said this morning the last of the stroke patients in the initial dosing group has been treated with the group’s new stem cell therapy.
NeoStem To Drive Shareholder Value, Says Rodman & Renshaw
NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.
Renovo Actively Progressing With Plans To Maximize Returns After Juvista Failure
Renovo Group (LON:RNVO) confirmed today it will be left with £33 million if it presses ahead with plans to reduce its headcount by 100.
ImmunoCellular To Present Encouraging Phase 1 Study Results For Brain Tumour Treatment
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.
Access Pharmaceuticals Inks Deal To Expand MuGard Distribution
Access Pharmaceuticals announced Tuesday it has signed an agreement with eMax Health Systems to expand the distribution of the company’s MuGard treatment.
Valeant Pharmaceuticals to acquire Lithuania’s Sanitas for $442m
Valeant Pharmaceuticals said Tuesday that it agreed to buy Lithuania-based generic drug company Sanitas for €314 million in cash.